FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:31:165 | Prevalence and incidence of skin telangectasia and their association with clinical features: analysis of the European Scleroderma Trials and Research cohort Gemma Lepri1, Lorenzo Tofani2, Silvia Bellando Randone1, Veronica Batani3, Paolo Airò4, Patricia Carreira5, Joerg Henes6, Alexandra Balbir Gurman7, Florenzo Iannone8, Antonella Marcoccia9, Luc Mouthon10, Branimir Anic11, Carolina De Souza Müller12, Armine Haroyan13, Ana Cristina Cordeiro14, Serena Guiducci And Eustar Coll1. | 1University of Florence, Dept of Experimental and Clinical Medicine, AOU Careggi, Division of Rheumatology Florence Italy; 2University of Florence, Dept of Statistics, Informatics, Applications, Florence, Italy; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR, IRCCS San Raffaele, Milano, Italy; 4Scleroderma Unit, UOC Rheumatology and Clinical Immunology, ASST Spedali Civili, Brescia, Italy; 5Dept of Rheumatology, 12 de Octubre University Hospital, Madrid, Spain; 6Centre for Interdisciplinary Rheumatology, Immunology and autoimmune diseases INDIRA, University Hospital Tuebingen, Tuebingen, Germany; 7Rheumatology Institute, Rambam Health Care Campus Haifa Israel; 8Dept of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, Italy; 9Interdisciplinary Reference Center for Systemic Sclerosis CRIIS Sandro Pertini Hospital, Rome, Italy; 10Dept of Internal Medicine, Cochin Hospital, Paris Cité University, Paris, France; 11Div Clinical Immunology and Rheumatology, Dept Internal Medicine, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia; 12Rheumatology Division, Hospital de Clínicas da Universidade Federal do Parana, Curitiba, Brazil; 13Dept of Rheumatology, Yerevan State Medical University of Armenia, Yerevan, Armenia; 14Servico Reumatologia Hospital Garcia de Orta Almada, Almada, Portugal.
144 -
PO:32:176 | Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease: results from a European Scleroderma Trials and Research cohort study Devis Benfaremo1, Corrado Campochiaro2, Gábor Kumánovics3, Christina Bergmann4, Elisabetta Zanatta5, David Launay6, Serena Guiducci7, Mickael Martin8, Carolina De Souza Müller9, Carlomaurizio Montecucco10, Luc Mouthon11, Gabriella Szucs12, Kastriot Kastrati13, Marie-Elise Truchetet14, Madelon Vonk15, Francesco Del Galdo16, Marco Matucci-Cerinic2, Gianluca Moroncini1, Yannick Allanore17. | 1Department of Clinical and Molecular Sciences, Marche Polytechnic University, Marche University Hospital, Ancona, Italy; 2Vita-Salute San Raffaele University, San Raffaele Hospital, Milano, Italy; 3University of Pécs, Department Of Rheumatology And Immunology, Pécs, Hungary; 4University Hospital Erlangen, Department Internal Medicine 3, Erlangen, Germany; 5Padova University Hospital, Rheumatology Unit, Padova, Italy; 6Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Lille, France; 7University of Florence, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy; 8Poitiers University Hospital, Department of Internal Medicine Poitiers France; 9Hospital de Clinicas da Universidade Federal do Parana Curitiba Brazil; 10Università di Pavia e IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy; 11Hôpital Cochin, Department of Internal Medicine, Paris, France; 12University of Debrecen, Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary; 13Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria; 14CHU de Bordeaux, Rheumatology department, Bordeaux, France; 15Radboudumc, Department of Rheumatology Nijmegen The Netherlands; 16Leeds Raynauds and Scleroderma Program, NIHR Biomedical Research Centre, Leeds, United Kingdom; 17Université Paris Cité, Cochin Hospital, Rheumatology Department, Paris, France.
146 -
PO:33:190 | Travel distance to tertiary healthcare reflects disease severity and medication access in systemic sclerosis patients: insights from the Italian systemic sclerosis progression investigation registry of the Italian Society of Rheumatology Camilla Teresa Magnanimi1, Enrico De Lorenzis1, Gerlando Natalello1, Fabio Cacciapaglia2, Rossella De Angelis3, Edoardo Cipolletta3, Maria Antonietta D'Agostino1, Veronica Cudullo4, Giacomo De Luca5, Dilia Giuggioli6, Francesca Ingegnoli7, Valeria Riccieri8, Lorenzo Dagna5, Fiorenzo Iannone9, Clodoveo Ferri6, Marco Matucci Cerinic5, Silvia Laura Bosello1. | 1Division of Rheumatology and Clinical Immunology, Catholic University of the Sacred Heart, Fondazione Policlinico Univer, Roma, Italy; 2Department of Medicine and Surgery, LUM University Giuseppe De Gennaro Casamassima e Rheumatology Service Miulli Ge, Bari, Italy; 3Rheumatology Unit - Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy; 4Department of Rheumatology, Policlinico San Matteo, Pavia, Italy; 5Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR, IRCCS San Raffaele Scientific Institute, Vita-Salu, Milano, Italy; 6Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 7Division of Clinical Rheumatology, ASST Pini, Dept. of Clinical Sciences e Community Health, Research Center for Adult a, Milano, Italy; 8Department of Rheumatology, La Sapienza University of Rome, Roma, Italy; 9Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, Italy.
147 -
CO:09:6 | Risk of disease flare during pregnancy and postpartum in inflammatory arthritis: association with therapy discontinuation in the prospective P-RHEUM.it study Dina Zucchi1, Chiara Tani1, Francesca Crisafulli2, Alessia Gatti2, Maria Gerosa3, Cecilia Chighizola3, Melissa Padovan4, Salvatore D'Angelo5, Florenzo Iannone6, Maria Sole Chimenti7, Claudia Lomater8, Francesca Serale9, Veronique Ramoni10, Oscar Epis11, Bernd Raffeiner12, Ariela Hoxha13, Andrea Doria14, Leonardo Santo15, Valentina Canti16, Francesca Bellisai17, Giovanna Cuomo18, on behalf of the P-Rheumit Investigators19, Greta Carrara20, Cristina Di Nicola20, Davide Rozza20, Carlo Alberto Scirè20, Maria Chiara Gerardi11, Angela Tincani2, Laura Andreoli2, Marta Mosca1. | 1Rheumatology Unit, University of Pisa and Azienda Ospedaliero Universitaria Pisana; 2Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia; 3Clinical Rheumatology Division, ASST Gaetano Pini-CTO and University of Milano; 4Rheumatology Unit, Azienda Ospedaliero-Universitaria S. Anna and University of Ferrara; 5Rheumatology Department of Lucania - San Carlo Hospital, Potenza; 6Rheumatology Unit, DiMePRE-J, University of Bari; 7Department of Systems Medicine, Rheumatology, Allergology and Clinical Immunology, University of Rome-Tor Vergata, Roma; 8Torino Academic Rheumatology Center, A.O. Mauriziano di Torino, University of Torino; 9Rheumatology Unit, ASL CN1 Cuneo; 10Internal Medicine Department, ASST Lodi - Ospedale Maggiore di Lodi; 11Division of Rheumatology, Multispecialist Medical Department, Grande Ospedale Metropolitano Niguarda, Milano; 12Department of Rheumatology, Central Hospital of Bolzano SABES-ASDAA, Bolzano; 13General Medicine and Thrombosis and Hemorrhagic Unit, Department of Medicine, University of Padova; 14Rheumatology Unit, Department of Medicine, University of Padova; 15Rheumatology Unit, Mons. Dimiccoli Hospital, Barletta; 16Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milano; 17Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena; 18Precision Medicine Department, University of Campania L. Vanvitelli, Napoli; 19The Italian Society for Rheumatology; 20Epidemiology Research Unit of the Italian Society for Rheumatology, Milano, Italy
141 -
PO:31:172 | Age and timing of onset of Raynaud's phenomenon and first non-Raynaud sign/symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the systemic sclerosis progression investigation registry of the Italian Society for Rheumatology Silvia Peretti1, Cosimo Bruni2, Silvia Laura Bosello3, Fabio Cacciapaglia4-5, Corrado Campochiaro6-7, Veronica Codullo8, Lorenzo Dagna6-7, Rossella De Angelis9, Giacomo De Luca6-7, Dilia Giuggioli10, Serena Guiducci1, Florenzo Iannone4, Francesca Ingegnoli11, Valeria Riccieri12, Marco Matucci Cerinic6-7, Clodoveo Ferri10-13, Silvia Bellando Randone1. | 1Division of Rheumatology, Scleroderma Unit, Department of Experimental and Clinical Medicine, University of Florence, AO, Firenze, Italy; 2Division of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 3Rheumatology Division, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli- IRCCS, Roma, Italy; 4Rheumatology Unit, Department of Precision and Regenerative Medicine-Ionian Area, University of Bari Aldo Moro, Bari, Italy; 5Reumatology Service, Internal Medicine Unit F.Miulli General Hospital, Acquaviva delle Fonti -Department of Medicine a, Bari, Italy; 6Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR, Inflammation, Fibrosis and Ageing initiative INFL, Milano, Italy; 7Vita-Salute San Raffaele University, Milano, Italy; 8Department of Internal Medicine and Therapeutics, Università di Pavia, Italy; Division of Rheumatology, Fondazione IRCCS, Pavia, Italy; 9Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy; 10Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 11Division of Clinical Rheumatology, ASST Pini, Dept. of Clinical Sciences and Community Health, Research Center for Adul, Milano, Italy; 12Department of Rheumatology, Sapienza University of Rome, Roma, Italy; 13Rheumatology Clinic Madonna dello Scoglio Crotonei, Crotone, Italy.
148 -
From anatomy to therapy: the historical journey to cortisone
1900PDF: 38SUPPLEMENTARY MATERIAL: 99 -
PO:26:096 | From free text to diagnosis: a Natural Language Processing approach for identifying rheumatoid and psoriatic arthritis in the Emergency Department Antonio Tonutti1|2, Pierandrea Morandini3, Cosimo Faeti3, Nicoletta Luciano1|2, Saverio D'Amico3, Antonio Voza1|4, Victor Savevski3, Carlo Selmi1|2 | 1Department of Biomedical Sciences, Humanitas University Pieve Emanuele, Milan, Italy; 2Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; 3Artificial Intelligence Unit, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; 4Emergency Department, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy
25 -
PO:14:193 | Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial Megan EB Clowse1, Marta Mosca2, David A Isenberg3, Joan T Merrill4, Thomas Dörner5, Michelle Petri6, Edward M Vital7|8, Eric F Morand9, Teri Jimenez10, Stephen Brookes11, Janine Gaiha-Rohrbach12, Christophe Martin13, Annette Nelde14, Christian Stach15 | 1Duke University - Division of Rheumatology and Immunology Durham, USA; 2University of Pisa - Rheumatology Unit, Department of Clinical and Experimental Medicine Pisa, Italy; 3University College London - Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine London, United Kingdom; 4Oklahoma Medical Research Foundation Oklahoma City, USA; 5Charité Universitätsmedizin Berlin - Department of Medicine/Rheumatology and Clinical Immunology Berlin Germany; 6Johns Hopkins University School of Medicine Baltimore, USA; 7University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds, United Kingdom; 8Leeds Teaching Hospitals NHS Trust - NIHR Leeds Biomedical Research Centre Leeds, United Kingdom; 9Monash University - Centre for Inflammatory Diseases Melbourne, Australia; 10UCB Raleigh, USA; 11Biogen Maidenhead, United Kingdom; 12Biogen Cambridge, USA; 13UCB Slough, United Kingdom; 14Biogen Baar, Switzerland; 15UCB Monheim am Rhein, Germany
40 -
The diagnostic utility of miRNA21 in systemic sclerosis
969PDF: 116SUPPLEMENTARY MATERIAL: 31 -
PO:03:034 | Inhibition of Radiographic Progression with Bimekizumab Treatment Observed in bDMARD-Naïve Patients with Active Psoriatic Arthritis at 2 Years: Results from a Phase 3 Study and its Open-Label Extension Laura C Coates1, M Elaine Husni2, Mitsumasa Kishimoto3, Proton Rahman4, Philipp Sewerin5, Enrique R Soriano6, Barbara Ink7, Rajan Bajracharya7, Jason Coarse8, Philip J Mease9, Emanuela Mazzola10, Peter Nash11 | 1NDORMS, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust Oxford, United Kingdom; 2Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Cleveland, USA; 3Department of Nephrology and Rheumatology, Kyorin University School of Medicine Tokyo, Japan; 4Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Memorial University of Newfoundland St. Johns, Canada; 5Rheumazentrum Ruhrgebiet, University Hospital of the Ruhr University Bochum Herne Germany; 6Hospital Italiano de Buenos Aires and University Institute Hospital Italiano de Buenos Aires Buenos Aires, Argentina; 7UCB Slough, United Kingdom; 8UCB Morrisville, USA; 9Department of Rheumatology, Providence-Swedish Medical Center and University of Washington Seattle, USA; 10UCB Milan, Italy; 11School of Medicine, Griffith University, Brisbane, Australia
39 -
Paratenon effusion of the Achilles tendon: a rare finding
1197PDF: 114SUPPLEMENTARY VIDEO: 133 -
PO:02:021 | Sustained Improvements with Bimekizumab in Pain, Morning Stiffness, Fatigue, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 3-Year Results from Two Phase 3 Studies Victoria Navarro-Compán1, Uta Kiltz2|3, Philip J Mease4, Maureen Dubreuil5, Karl Gaffney6, Atul Deodhar7, Christine De La Loge8, Diana Voiniciuc9, Jason Coarse10, Ilaria Spadafora11, Helena Marzo-Ortega12 | 1La Paz University Hospital, IdiPaz, Department of Rheumatology Madrid Spain; 2Ruhr-University Bochum Bochum Germany; 3Rheumazentrum Ruhrgebiet Herne, Germany; 4Department of Rheumatology, Swedish Medical Center and Providence St. Joseph Health and University of Washington Seattle, USA; 5Boston University School of Medicine, Department of Rheumatology Boston, USA; 6Norfolk and Norwich University Hospital NHS Trust, Department of Rheumatology Norfolk, United Kingdom; 7Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases Portland, USA; 8UCB Brussels, Belgium; 9UCB Slough, United Kingdom; 10UCB Morrisville, USA; 11UCB Milan, Italy; 12NIHR Leeds Biomedical Research Centre, University of Leeds Leeds, United Kingdom
17 -
PO:32:187 | AI-assisted reading outperforms visual scoring of pulmonary CT scans to predict interstitial lung disease progression in systemic sclerosis Francesca Motta1, Antonio Tonutti1, Federica Catapano2, Gianluca Sellaro2, Francesco Amati3, Anna Stainer3, Calogero Messana2, Stefano Erba1, Stefano Aliberti3, Marco Francone2, Carlo Selmi1, Maria De Santis1 | 1Humanitas University and IRCCS Humanitas Research Hospital, Department of Rheumatology and Clinical Immunology Rozzano, Milan, Italy; 2IRCCS Humanitas Research Hospital, Department of Radiology Rozzano, Milan, Italy; 3IRCCS Humanitas Research Hospital, Respiratory Unit Rozzano, Milan, Italy
16 -
PO:31:174 | Increased frequency of anti-RNA polymerase 3 antibodies in patients with systemic sclerosis and silicone breast implants: a multicentre study from the international European Scleroderma Trials and Research cohort Maria Grazia Lazzaroni1, Yolanda Braun-Moscovici2, Elda Piovani1, Claudia Barison1, Liala Moschetti1, Veronica Batani3, Corrado Campochiaro3, Michal Tomcik4, Francesca Motta5, Maria De Santis5, Petros P. Sfikaki6, Masataka Kuwana7, Brigitte Granel8, Roberta Foti9, Virginia Berlingiero10, Joana Caetano11, Yannick Allanore12, Alexandra Balbir-Gurman2, Marco Matucci Cerinic3, Franco Franceschini1, Paolo Airò1. | 1ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy; 2Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion-Israeli Institute of Tecnology, Haifa, Israel; 3Vita-Salute San Raffaele University, San Raffaele Hospital, Milano, Italy; 4Institute of Rheumatology, Praga, Czech Republic; 5IRCCS Humanitas Research Hospital; Humanitas University, Milano, Italy; 6Joint Rheumatology Program, Medical School, National Kapodistrian University of Athens Atene GREECE; 7Nippon Medical School Hospital Tokyo Japan; 8Hôpital Nord de Marseille; Aix-Marseille Université Marsiglia France; 9AOU Policlinico G. Rodolico San Marco, Catania, Italy; 10Azienda Ospedaliera Universitaria Senese, Siena, Italy; 11Fernando Fonseca Hospital, Amadora, Portugal; 12Université Paris Cité, Cochin Hospital, Parigi, France.
136 -
PO:26:095 | Educational online webinars of European Reference Network on rare and complex connective tissue and musculoskeletal diseases for patients, caregivers and healthcare professionals: six years' experience Emanuele Gotelli1|2, Rosanna Campitiello1|3, Eric Hachulla4|5|6, Vanessa Smith7|8|9, Joao Eurico Fonseca10|11, Tadej Avcin12|13, Gabriele Simonini14|15, Silvia Aguilera16, Lisa Matthews17, Charissa Frank18, Wiebke Lautré19, Monica Testoni20, Diana Marinello20, Rosaria Talarico20, Marta Mosca20, Maurizio Cutolo1|2. | 1Department of Internal Medicine and Specialties, University of Genova, Genova, Italy; 2IRCCS Ospedale Policlinico San Martino, Genova, Italy; 3Department of Experimental Medicine DIMES, University of Genova, Genova, Italy; 4Institute for Translational Research in Inflammation INFINITE, Université de Lille, Lille, France; 5INSERM, Lille, France; 6Centre de référence des maladies autoimmunes systemiques rares du Nord et Nord-Ouest de France CeRAINO, Lille, France; 7Department of Internal Medicine, University of Ghent, Ghent University Hospital, Ghent, Belgium; 8Department of Rheumatology, University of Ghent, Ghent University Hospital, Ghent, Belgium; 9Unit for Molecular Immunology and Inflammation, Flemish Institute for Biotechnology, Inflammation Research Center, Ghent, Belgium; 10Centro Hospitalar Universitário Lisboa Norte EPE, Serviço de Reumatologia e Doenças Ósseas Metabólicas Lisboa Portugal; 11Universidade de Lisboa, Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular João Lobo Antunes Lisboa Portugal; 12University Children Hospital, University Medical Center Ljubljana, Ljubljana, Slovenia; 13University of Ljubljana, Department of Paediatrics, Ljubljana, Slovenia; 14University of Florence, NEUROFARBA Department, Firenze, Italy; 15Meyer Children Hospital IRCCS, Rheumatology Unit, Firenze, Italy; 16Spanish Association for Antiphospholipid Syndrome, Elche, Spain; 17Relapsing Polychondritis Awareness and Support, Worcester, United Kingdom; 18Flemish Association for Hereditary Connective Tissue Disorders, Koersel, Belgium; 19CHU Bordeaux Pellegrin, Centre de Références Maladies Auto-Immunes Systémiques Rares, Bordeaux, France; 20Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
120 -
PO:31:167 | Increased M2 pro-fibrotic marker expression in circulating monocytes and cultured monocyte-derived macrophages in systemic sclerosis patients with progressive interstitial lung disease Vanessa Smith1|2, Stefano Soldano3, Rosanna Campitiello3|5, Emanuele Gotelli3|4, Paola Montagna3, Elvis Hysa3|5, Tamara Vojinovic3|4, Carmen Pizzorni3|4, Sabrina Paolino3|4, Alberto Sulli3|4, Maurizio Cutolo3|4. | 1Department of Internal Medicine and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; 2Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Centre, Ghent, Belgium; 3Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, Genova, Italy; 4IRCCS Ospedale Policlinico San Martino, Genova, Italy; 5Department of Experimental Medicine DIMES, University of Genova, Genova, Italy.
130 -
PO:06:079 | Weighing the burden: how body mass index shapes clinical outcomes in rheumatoid arthritis. Insights from a large Italian cohort Marco Capodiferro1, Marco Fornaro1, Gian Luca Erre2, Matteo Piga3, Elena Bartoloni Bocci4, Andreina Manfredi5, Ennio Giulio Favalli6, Maria Sole Chimenti7, Serena Guiducci8, Eleonora Celletti9, Addolorata Corrado10, Alessandro Giollo11, Simone Parisi12, Ivan Giovannini13, Elisa Gremese14, Garifallia Sakellariou15, Ombretta Viapiana16, Fabiola Atzeni17, Francesca Romana Spinelli18, Fabio Cacciapaglia1|19. | 1Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J University of Bari, Bari, Italy; 2Dipartimento di Scienze Mediche, Chirurgiche e Sperimentali, Università degli Studi di Sassari, Sassari, Italy; 3Rheumatology Unit, AOU Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; 4Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 5Rheumatology Unit, Azienda Ospedaliera Universitaria Policlinico of Modena, Modena, Italy; 6Dpt of Rheumatology, G. Pini Institute, Milano, Italy; 7Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; 8Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy; 9Rheumatology Unit, SS Annunziata Hospital, Chieti, Italy; 10Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy; 11Rheumatology Unit, Department of Medicine, University of Padova Hospital Trust, Padova, Italy; 12Rheumatology Department, A.O.U. Città della Salute e della Scienza, Torino, Italy; 13Rheumatology Department, Santa Maria della Misericordia Hospital, Udine, Italy; 14Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy; 15Department of Internal Medicine and Therapeutics, University of Pavia, Istituti Clinici Scientifici Maugeri, Pavia, Italy; 16Rheumatology Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy; 17Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina, Italy; 18Reumatology Unit, Department of Internal, Anesthesiological, and Cardiovascular Clinical Sciences, Sapienza University, Roma, Italy; 19Miulli General Hospital Acquaviva - Department of Medicine and Surgery, LUM F. De Gennaro University, Casamassima (BA), Acquaviva delle Fonti (BA), Italy.
155 -
PO:02:016 | Real-world evidence of upadacitinib over two years in Italian patients with axial spondyloarthritis Mariagrazia Lorenzin1, Giacomo Cozzi1, Stefano Gentileschi2, Michele Maria Luchetti Gentiloni3, Antonio Carletto4, Maria Sole Chimenti5, Maria Manara6, Luca Quartuccio7, Rosario Foti8, Salvatore D'Angelo9, Ariela Hoxha10, Carlo Selmi11, Bernd Raffeiner12, Alessandro Giollo1, Alberto Cauli13, Carlo Salvarani14, Fabiola Atzeni15, Roberta Ramonda1, Sir Study Group Spa E Psa Antonio Spadaro16. | 1Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy; 2Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy; 3Clinica Medica, Ospedali Riuniti Ancona University Hospital, Ancona; Department of Clinical and Molecular Sciences, Ancona, Italy; 4Rheumatology Unit, Department of Medicine, AOUI University of Verona, Verona, Italy; 5Rheumatology, allergology and clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Roma, Italy; 6Humanitas San Pio X, Milano, Italy; 7University of Udine, Academic Hospital Santa Maria della Misericordia, Udine, Italy; 8Rheumatology Unit, A.O.U. Policlinico S. Marco, Catania, Italy; 9Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; 10Internal Medicine Unit, Thrombotic and Hemorrhagic Center, Department of Medicine-DIMED, University of Padua, Padova, Italy; 11Department of Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 12Department of Rheumatology, Teaching Hospital of the Paracelsius Medical Hospital of Bolzano ASAA-SABES, Bolzano, Italy; 13Rheumatology Unit, Department of Medical Sciences, AOU and University of Cagliari, Monserrato, Cagliari, Italy; 14Department of Rheumatology, Azienda USL-IRCCS di Reggio Emilia and Università di Modena and Reggio Emilia, Reggio Emilia, Italy; 15Rheumatology Unit, University of Messina, Messina, Italy; 16Società Italiana di Reumatologia, Milano, Italy.
163 -
PO:33:192 | Hand Microvascular Damage Is Associated with Hand Bone Loss in Systemic Sclerosis Rosanna Campitiello1|3, Sabrina Paolino1|2, Andrea Casabella1|2, Giulia Davoli1|2, Elisa Caratto1|2, Emanuele Gotelli1|2, Elvis Hysa1|2, Carmen Pizzorni1|2, Vanessa Smith4|5, Alberto Sulli1|2, Maurizio Cutolo1|2 | 11. Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medic Genova, Italy; 2IRCCS Ospedale Policlinico San Martino Genova, Italy; 3Department of Experimental Medicine DIMES, University of Genova Genova, Italy; 4Department of Internal Medicine and Department of Rheumatology, Ghent University Hospital Ghent, Belgium; 5Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Centre, Ghent, Belgium
18
